MedPath

Activated Protein C versus placebo in the treatment of Inflammatory or Infectious ALI/ARDS (INFALI): a pathophysiological study on pulmonary microvascular permeability, apoptosis, inflammation and coagulation.

Recruiting
Conditions
Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS)
Registration Number
NL-OMON21017
Lead Sponsor
VU University Medical Center (VUmc), department of Intensive Care
Brief Summary

will be written after analysis of results

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
106
Inclusion Criteria

1. age 18 - 75 years

2. weight < 135 kg

Exclusion Criteria

1. APACHE II score: 25 and more

2. 2 or more failing organs

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
67-Gallium pulmonary leak index (PLI)<br>
Secondary Outcome Measures
NameTimeMethod
1. Lung Injury Score<br /><br>2. inflammatory mediators/biomarkers (blood, mini-BAL)<br /><br>3. coagulation and fibrinolysis markers (blood, mini-BAL)<br /><br>4. apoptosis markers (blood, mini-BAL)<br /><br>5. mortality<br /><br>6. extra-vascular lung water <br /><br>7. gas exchange (compliance, PaO2/FiO2)<br /><br>8. radiographic abnormalities (X-ray, CT)<br /><br>9. change of ventilatory mode (noninvasive vs. invasive)<br /><br>10. duration of mechanical ventilation <br />
© Copyright 2025. All Rights Reserved by MedPath